{
  "title": "M21-1, Part V, Subpart iii, Chapter 4, Section A - Respiratory Conditions",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180967/M21-1-Part-V-Subpart-iii-Chapter-4-Section-A-Respiratory-Conditions",
  "content": "<--\nPrevious Section\nNext Section\n-->\nOverview\nIn This Section\nThis section contains the following topics:\nTopic\nTopic Name\n1\nBasic Rating Principles for Respiratory Conditions\n2\nSleep Apnea and Related Disabilities\n3\nRespiratory Tract Infections\n4\nOther Respiratory Disorders\n1\n.\nBasic Rating Principles for Respiratory Conditions\nIntroduction\nThis topic contains basic rating principles for respiratory conditions, including\nprohibition of separate evaluations for certain coexisting respiratory disabilities\nevaluating coexisting respiratory disabilities\nexample 1 - evaluating coexisting respiratory disabilities\nexample 2 - evaluating coexisting respiratory disabilities\nrequirement for pulmonary function tests (PFTs)\nassigning disability evaluations based on the results of PFTs\npost-bronchodilator studies, requirements, and evaluations\n, and\ndiffusion capacity of the lung for carbon monoxide (DLCO) testing\n.\nChange Date\nApril 18, 2018\nV.iii.4.A.1.a\n.\nProhibition of Evaluations for Certain Coexisting Respiratory Disabilities\n38 CFR 4.96(a)\nprohibits the assignment of separate evaluations for co-existing respiratory conditions rated under\n38 CFR 4.97, diagnostic codes (DCs) 6600 through 6817 and 6822 through 6847\n.\n38 CFR 4.97, DCs 6819 and 6820\n(malignant and benign neoplasms) are rated on residuals, including any residual disability of the respiratory system.  Therefore, where there is lung or pleural involvement, separate evaluations under\n38 CFR 4.97, DCs 6819 and 6820\nare prohibited.  If an evaluation has already been assigned under either\n38 CFR 4.97, DCs 6819 or 6820\n, separate evaluations are also prohibited under\n38 CFR 4.97, DCs 6600 through 6817 and 6822 through 6847\n.\nReference\n:  For more information on pyramiding, see\n38 CFR 4.14\nM21-1, Part V, Subpart ii, 3.D.2.b\n, and\nEsteban v. Brown\n, 6 Vet.App. 259 (1994).\nV.iii.4.A.1.b\n.\nEvaluating Coexisting Respiratory Disabilities\nUnder\n38 CFR 4.96(a)\n, when there are coexisting respiratory disabilities for which multiple evaluations cannot be assigned\na single rating will be assigned under the DC which reflects the predominant disability, and\nthat evaluation will be elevated to the next higher evaluation, when the severity of the overall disability warrants it.\nException\n:  In cases protected by the provisions of\nPub\nlic Law 90-493\n, the graduated ratings of 50 and 30 percent for inactive tuberculosis will not be elevated.\nThe Veterans Benefits Management System – Rating Evaluation Builder is programmed to appropriately apply the provisions of\n38 CFR 4.96(a)\nbut\nit is critical that\nthe user input the symptoms that support the elevation, and\nthe symptoms coincide with the criteria listed in the rating schedule.\nRefer to the table below for instructions on proper application of the\n38 CFR 4.96(a)\nprovision on assigning an evaluation in cases of multiple qualifying coexisting respiratory disabilities.\nStep\nAction\n1\nDetermine which of the coexisting respiratory conditions is the predominant disability.\nImportant\n:\nTo determine the predominant disability, determine the evaluation each condition would warrant on its own.  The condition that has the highest disability evaluation is the predominant disability.\nIf the same evaluation would be assigned to each, go through the analysis in the steps, alternatively treating each condition as the predominant one to see if one alternative provides a more advantageous outcome to the Veteran.\n2\nDetermine if there are symptoms of the non-predominant disability that do not overlap with those of the predominant disability.\nIf\nyes\n, go to Step 3.\nIf\nno\n, go to Step 4.\n3\nReevaluate the predominant disability but this time also consider the non-overlapping symptoms of the non-predominant disability.\nImportant\n:  The non-overlapping symptoms must support a higher evaluation when applied to the DC criteria being utilized for the predominant disability.\nDetermine if the resultant evaluation is higher than the evaluation for the symptoms of the predominant disability alone (as derived in Step 1).\nIf\nyes\n, go to Step 5.\nIf\nno\n, go to Step 4.\n4\nRate the coexistent disabilities together under the rating criteria for the predominant disability\nwithout elevation\nto the next higher evaluation.\nNo further action necessary.\n5\nRate the coexistent disabilities together under the rating criteria for the predominant disability and elevate to the next higher evaluation.\nNo further action necessary.\nImportant\n:\nThe “next higher level of evaluation” is the lowest evaluation specified in the DC for the predominant disability\nthat provides greater compensation than the evaluation derived in\nStep 1\n(the evaluation that would be supported by only the symptoms of the predominant disability without the symptoms of the lesser disability).\nDo not simply add 10 percent.\nAlthough elevation remains a legal option under the existing regulatory language, because evaluations in the specified DCs overwhelmingly use mostly-overlapping and mostly-objective criteria, in many cases the result of the analysis specified in the table will be a conclusion that elevation is not appropriate.\nReference\n:  For more information on application of\n38 CFR 4.96(a)\n, see\nUrban v. Shulkin\n, 29 Vet.App. 82 (2017).\nV.iii.4.A.1.c\n.\nExample 1 - Evaluating Coexisting Respiratory Disabilities\nSituation\n:  Sleep apnea (\n38 CFR 4.97, DC 6847\n) warrants an evaluation of 50 percent based on the need for a continuous positive airway pressure (CPAP) machine.  Chronic obstructive pulmonary disease (COPD) (\n38 CFR 4.97, DC 6604\n) is coexistent and warrants a 30-percent evaluation based on pulmonary function tests (PFTs).\nResult\n:  The predominant condition is the sleep apnea as it justifies a higher evaluation.  There are no non-overlapping symptoms of COPD to establish any of the criteria for which the next higher (100 percent) evaluation could be assigned for sleep apnea:  chronic respiratory failure with carbon dioxide retention or cor pulmonale, or need for tracheostomy.  Therefore, elevation is not appropriate.\nV.iii.4.A.1.d\n.\nExample 2 - Evaluating Coexisting Respiratory Disabilities\nSituation\n:  Asbestosis (\n38 CFR 4.97, DC 6833\n) warrants an evaluation of 30 percent based on diffusion capacity of the lung for carbon monoxide (DLCO).  Asthma (\n38 CFR 4.97, DC 6602\n) is coexistent and warrants a 30-percent evaluation based on inhalational anti-inflammatory medication.\nResult\n:  Neither is predominant as each would justify a 30-percent evaluation.   The use of medications is not considered in next higher criteria for\n38 CFR 4.97, DC 6833\n(Forced Vital Capacity (FVC) of 50 to 64 percent of predicted; DLCO of 40-55 percent of predicted; or, maximum exercise capacity of less than 15 ml/kg/min of oxygen consumption with cardiorespiratory limitation) and does not provide any basis for elevation. Conversely, the DLCO result for asbestosis is not considered in the next higher criteria for\n38 CFR 4.97, DC 6602\n(Forced Expiratory Volume in one second (FEV-1) of 40 to 55 percent predicted; FEV-1/FVC of 40 to 55 percent; at least monthly visits to a physician for required care of exacerbations; or, intermittent (at least three per year) courses of systemic (oral or parenteral) corticosteroids).  Therefore, elevation is not appropriate.\nV.iii.4.A.1.e\n.\nRequirement for PFTs\nPFT results are required for\n38 CFR 4.97, DC 6600, 6603, 6604, 6825-6833, and 6840-6845\nas specified at\n38 CFR 4.96(d)\nexcept when\nthe results of a maximum exercise capacity test are of record and are 20 milliliters/per kilogram of body weight per minute (ml/kg/min) or less\npulmonary hypertension has been diagnosed\ncor pulmonale has been diagnosed\nright ventricular hypertrophy has been diagnosed\nthere have been one or more episodes of acute respiratory failure, or\noutpatient oxygen therapy is required.\nNotes\n:\nIf a maximum exercise capacity test is not of record, evaluate based on alternative criteria.\nA diagnosis of pulmonary hypertension requires objective documentation by an echocardiogram or cardiac catheterization.\nWhen the rating criteria for a disability not regulated by\n38 CFR 4.96(d)\ninclude PFTs among the potential methods for assigning a disability evaluation, such as\n38 CFR 4.97, DC 6602\nfor asthma, PFTs are not required to evaluate the disability.  However, if PFTs were previously utilized to assign a disability evaluation and consideration is being given to a reduced evaluation, apply\n38 CFR 3.344(a)\n.  When the prior evaluation was assigned based on PFTs, the current examination must also include PFTs if a reduced evaluation due to improvement is being considered\n.\nReference\n:  For more information on when PFTs are required, see\n38 CFR 4.96(d)\n.\nV.iii.4.A.1.f\n.\nAssigning Disability Evaluations Based on the Results of PFTs\nThe table below contains instructions for assigning disability evaluations based on the results of PFTs.\nThis table applies to\n38 CFR 4.97, DC 6600, 6603, 6604, 6825-6833, and 6840-6845\nas specified at\n38 CFR 4.96(d)\n.\nIf …\nAnd …\nThen ...\nPFTs are not consistent with clinical findings\nthe examiner\ndoes\nnot\nstate why PFTs are not a valid indication of respiratory disability\nevaluate based on PFTs.\nPFTs are not consistent with clinical findings\nthe examiner states why PFTs are not a valid indication of respiratory disability\nevaluate based on alternative criteria.\nthere is a disparity between PFT results  (FEV-1, FVC, FEV-1/FVC, DLCO)\nthe evaluation would differ depending on the test result used\nuse the test result that the examiner states most accurately reflects the level of disability.\nFEV-1 is greater than 100 percent\nFVC is greater than 100 percent\ndo not assign a compensable evaluation based on a decreased FEV-1/FVC ratio.\nDLCO is not of record\nthe examiner states why DLCO would not be useful or valid\nevaluate based on alternative criteria.\nDLCO is not of record\nthe examiner\ndoes not\nstate why DLCO would not be useful or valid\nreturn the examination as insufficient and request clarification.\nV.iii.4.A.1.g\n.\nPost-Bronchodilator Studies, Requirements, and Evaluations\nPost-bronchodilator studies are required when PFTs are done for disability evaluation purposes\nfor disabilities rated under\n38 CFR 4.97, DC 6600, 6603, 6604, 6825-6833, and 6840-6845\nexcept\nwhen\nthe results of pre-bronchodilator PFTs are normal\nthe examiner determines that post-bronchodilator studies should not be done and states why, or\nusing the DLCO score values (Clinicians have stated that bronchodilator use has no effect on DLCO values.)\nWhen evaluating based on PFTs, use post-bronchodilator results unless the post-bronchodilator results were poorer than the pre-bronchodilator results.  In those cases, use the pre-bronchodilator values for rating purposes.\nV.iii.4.A.1.h\n.\nDLCO Testing\nWhen utilizing DLCO to evaluate a respiratory disability, only test results recognized as DLCO or DLCO by the single breath method (DLCO (SB)) will be utilized for rating purposes.\nDLCO divided by alveolar volume (DLCO/VA) is a variant of DLCO (SB) in which the DLCO is divided by the alveolar volume of the lungs. There is no provision for considering DLCO/VA under\n38 CFR 4.96\nor\n38 CFR 4.97\n. Consequently, DLCO/VA cannot be utilized for rating purposes.\n2\n.\nSleep Apnea and Related Disabilities\nIntroduction\nThis topic contains general information about sleep apnea and related disabilities, including\nsleep apnea and sleep studies\nevaluating sleep apnea\nqualifying devices for sleep apnea treatment\nrequired use of a breathing assistance device\nprocessing claims for increase in sleep apnea\n, and\nconsidering upper airway resistance syndrome (UARS)\n.\nChange Date\nFebruary 19, 2019\nV.iii.4.A.2.a\n.\nSleep Apnea and Sleep Studies\nReceipt of medical evidence disclosing a diagnosis of sleep apnea without confirmation by a sleep study is sufficient to trigger the duty to assist for scheduling an examination if the other provisions of\n38 CFR 3.159(c)(4)\nhave been satisfied.  However, such evidence is\nnot\nsufficient to award service connection (SC) for sleep apnea.\nWhen clinical examination leads to the conclusion that symptoms of sleep apnea are present, the subsequent diagnosis of sleep apnea must be confirmed by sleep study for compensation purposes.\nDo not establish SC for sleep apnea that has not been confirmed by a sleep study.\nHowever, if clinical indicators of sleep apnea are not found on examination, a sleep study is not required to rule out the sleep apnea diagnosis.\nImportant\n:  Accept a home sleep study only if\nit has been clinically determined that the Veteran can be appropriately evaluated by a home sleep study, and\na competent medical provider has evaluated the results.\nReference\n:  For more information on types of medical providers qualified to provide medical evidence, see\nM21-1, Part IV, Subpart i, 3.A.1\n.\nV.iii.4.A.2.b\n.\nEvaluating Sleep Apnea\nEvaluate sleep apnea using the criteria in\n38 CFR 4.97, DC 6847\n(sleep apnea syndromes (obstructive, central, mixed).\nWhen determining whether the 50-percent criteria are met, the key consideration is whether use of a qualifying breathing assistance device is required by the severity of the sleep apnea.\nThere are two related considerations, which are\nwhether a device qualifies, as discussed in\nM21-1, Part V, Subpart iii, 4.A.2.c\n, and\nif use of a qualifying device is necessary, as discussed in\nM21-1, Part V, Subpart iii, 4.A.2.d\n.\nV.iii.4.A.2.c\n.\nQualifying Devices for Sleep Apnea Treatment\n38 CFR 4.97, DC 6847\nlists a CPAP machine as an example of a breathing assistance device for treatment of sleep apnea which is required for assignment of the 50 percent evaluation.\nOther qualifying breathing assistance devices include\nother positive airway pressure machines (automatic positive airway pressure device (APAP); bilevel positive airway pressure device (BiPAP))\nnasopharyngeal appliances (nasal dilators; nasopharyngeal stents)\noral appliances (mandibular advancement devices (MAD); tongue-retaining mouthpieces), and\nimplanted genioglossal nerve stimulation devices.\nNote\n:  Positive airway pressure machines may also be called non-invasive positive pressure ventilation (NIPPV) or non-invasive ventilation (NIV).\nV.iii.4.A.2.d\n.\nRequired Use of a Breathing Assistance Device\nAssignment of the 50-percent evaluation for sleep apnea under\n38 CFR 4.97, DC 6847\nentails the required use of a breathing assistance device.  Consider the factors below in determining whether the criteria for required use of a breathing assistance device are satisfied.\nUse of a device absent a medical determination that the device is necessary does not qualify.  The regulation requires that the device be necessary, and this is a medical question.\nIf the competent medical evidence of record shows that use of a qualifying breathing assistance device is medically required, the fact that the claimant is not actually using it as prescribed is not relevant.\nV.iii.4.A.2.e\n.\nProcessing Claims for Increase in Sleep Apnea\nFollow the steps in the table below to process a claim for increase in sleep apnea.\nStep\nAction\n1\nIs there a sleep study confirming the diagnosis of sleep apnea?\nIf\nyes\n, go to Step 6.\nIf\nno\n, go to Step 2.\n2\nHas SC for sleep apnea been in effect for 10 years or more?\nIf\nyes\n, go to Step 6.\nIf\nno\n, go to Step 3.\n3\nRequest an examination with sleep study to confirm the diagnosis.\nGo to Step 4.\n4\nDoes the sleep study confirm the diagnosis of sleep apnea?\nIf\nyes\n, go to Step 6.\nIf\nno\n, go to Step 5.\n5\nPrepare a proposal to sever SC for sleep apnea in accordance with\n38 CFR 3.105(d)\n.\nReference\n:  For more information on preparing proposed rating decisions, see\nM21-1, Part X, Subpart ii, 3.D.1\n.\n6\nPerform any additional development as necessary, continue SC for sleep apnea, and assign an evaluation based on the evidence of record.\nV.iii.4.A.2.f\n.\nConsidering UARS\nUpper airway resistance syndrome (UARS) represents a progression toward the potential development of sleep apnea, caused by snoring.  However, UARS, in and of itself, does not meet the criteria of sleep-disordered breathing that defines sleep apnea and is not considered a ratable disability for compensation purposes.\nIn order to dispose of a claim for SC where only an assessment of UARS is shown, the rating activity must\ndeny SC in the absence of a diagnosed chronic disability\ncode the issue as analogous to sleep apnea under\n38 CFR 4.97, DC 6847\n, and\ninform the Veteran that a supplemental claim may be submited if a clinical diagnosis of sleep apnea is subsequently confirmed.\nExample\n:\nReferences\n:  For more information on\nsubthreshold diagnoses, see\nM21-1, Part V, Subpart ii, 3.C.1.b\nsleep disorders examination review, see\nM21-1, Part IV, Subpart i, 3.B.1.l\n, and\nusing analogous DCs, see\nM21-1, Part V, Subpart iv, 1.C.2.a and b\n, and\nM21-1, Part V, Subpart ii, 3.D.1.b\n.\n3\n.\nRespiratory Tract Infections\nIntroduction\nThis topic contains general information about respiratory tract infections, including\ntypes of chronic upper respiratory tract infections\nidentifying the cause of coexisting chronic upper respiratory tract infections\ncontinuous upper respiratory tract infections that first manifest after discharge\n, and\nrelationship between upper and lower respiratory tract infections\n.\nChange Date\nJanuary 31, 2018\nV.iii.4.A.3.a\n.\nTypes of Chronic Upper Respiratory Tract Infections\nChronic upper respiratory tract infections include\nchronic rhinitis\nchronic sinusitis\nchronic tonsillitis, and\nchronic laryngitis.\nV.iii.4.A.3.b\n.\nIdentifying the Cause of Coexisting Chronic Upper Respiratory Tract Infections\nThe cause of two or more coexisting chronic upper respiratory tract infections is commonly the same infectious process.  However, if two or more chronic infections persist over a period of years, give the probability of causation by separate types of organisms due weight.\nV.iii.4.A.3.c\n.\nContinuous Upper Respiratory Tract Infections That First Manifest After Discharge\nIf all respiratory conditions do not originate in service, there must be evidence of a fairly continuous infection in one or more parts of the upper respiratory tract to warrant SC for other conditions first manifest after discharge.\nCarefully consider the character of the infection and possible intervening causes.\nV.iii.4.A.3.d\n.\nRelationship Between Upper and Lower Respiratory Tract Infections\nThere may be a close relationship between disease of the upper respiratory tract and a subsequently-developing chronic process in the lower respiratory tract, especially in the bronchi.\n4\n.\nOther Respiratory Disabilities\nIntroduction\nThis topic contains general information about other respiratory disabilities, including\ndeviated nasal septum\nsinusitis\nconsidering allergic rhinitis within scope of claimed sinusitis\nrhinosinusitis\nallergic rhinitis\nconstrictive bronchiolitis\ncomplete organic aphonia and special monthly compensation (SMC)\nspontaneous pneumothorax\n, and\ngunshot wounds (GSWs) of muscle groups (MGs) I to IV and XXI\n.\nChange Date\nApril 22, 2022\nV.iii.4.A.4.a\n.\nDeviated Nasal Septum\nSC cannot be granted for a deviation of the nasal septum unless trauma is shown.\nReference\n:  For more information on traumatic nasal septum deviation see\n38 CFR 4.97, DC 6502\n.\nV.iii.4.A.4.b\n.\nSinusitis\nEvaluate sinusitis under\n38 CFR 4.97, DCs 6510 through 6514\n.\nWhen applying the higher of two possible evaluations under\n38 CFR 4.7\n, a history of radical surgery or repeated surgeries is\nnot\nrequired if the criteria under the rating formula are otherwise met.\nExample\n:  The application of\n38 CFR 4.7\nresults in an evaluation of 50 percent when the evidence shows\nchronic osteomyelitis,\nor\nnear constant sinusitis, characterized by\nheadaches\npain and tenderness of affected sinus, and\npurulent discharge,\nand\nno evidence of radical surgery or repeated surgery.\nReference\n:  For more information on the schedule of rating respiratory conditions, see\n38 CFR 4.97\n.\nV.iii.4.A.4.c\n.\nConsidering Allergic Rhinitis Within Scope of Claimed Sinusitis\nWhen a claim for SC for sinusitis is received but compensation examination reveals a diagnosis of allergic rhinitis and not sinusitis and associates the rhinitis with service, consider allergic rhinitis within scope of the claim for SC for sinusitis.  In this situation\ndo not return the examination for clarification of a diagnosis if the examination is otherwise sufficient\ngrant SC for allergic rhinitis if otherwise supported by the evidence of record, and\ndeny SC for sinusitis if sinusitis is not shown.\nReminder\n:  If both sinusitis and rhinitis are shown and the requirements for SC are met for both conditions, grant SC for each condition separately and  combine as usual under\n38 CFR 4.25\n.\nReference\n:  For more information on considering issues within scope of a claim, see\nM21-1, Part V, Subpart ii, 3.A.2\n, and\n38 CFR 3.155(d)(2)\n.\nV.iii.4.A.4.d\n.\nRhinosinusitis\nRhinosinusitis should be rated as a type of sinusitis, using the general rating formula and choosing the most appropriate DC from\n38 CFR 4.97, DC 6510 through 6514\n.  Select the DC for the type of sinusitis that most closely corresponds with the location of the rhinosinusitis.\nNote\n:\nDC 6599 analogous code indicator should precede the analogous sinusitis DC because rhinosinusitis is not listed in the rating schedule.\nRhinosinutis is a chronic disease associated with exposure to particulate matter, as provided in\n38 CFR 3.320(a)(2)\n.\nReference\n:  For more information on claims for SC for chronic diseases associated with exposure to particulate matter, see\nM21-1, Part VIII, Subpart ii, 2.A\n-\nC\n.\nV.iii.4.A.4.e\n.\nAllergic Rhinitis\n38 CFR 3.380\ndirects that diseases of allergic etiology are not to be disposed of routinely for compensation purposes as constitutional or developmental abnormalities.  When considering SC for allergic rhinitis, consider whether\nthe disability existed prior to service, and\nwhether the disability is chronic and persistent in relation to exposure to and removal from the allergen.\nThe determination as to service incurrence must be based on the whole evidentiary showing.\nExample\n:  Veteran claims SC for allergic rhinitis.  The nose and sinuses were normal at enlistment with no allergies noted.  During his 20-year military career, the Veteran was treated variably for symptoms of upper respiratory infection, congestion, rhinitis, seasonal allergic rhinitis, perennial allergic rhinitis, and seasonal allergies throughout service.  Clear diagnoses of allergies and allergic rhinitis were noted during service including on the retirement physical.  At the compensation examination, the Veteran reported episodic sinusitis and ongoing allergic rhinitis with seasonal symptoms and the use of medications for treatment.  Examination revealed no obstruction or deviation.  No rhinitis or sinusitis were active on examination.  The diagnosis was seasonal allergic rhinitis.\nResult\n:  The Veteran had a long and recurring history of complaints of, treatment for, and diagnosis of allergic rhinitis and upper respiratory symptoms during service.  There is no evidence of a pre-service history of allergic rhinitis.  Veteran is entitled to SC with a noncompensable evaluation for allergic rhinitis as evidence showed incurrence in service.\nV.iii.4.A.4.f\n.\nConstrictive Bronchiolitis\nConstrictive bronchiolitis (also known as bronchiolitis obliterans) is an inflammatory and fibrotic lesion of the terminal bronchioles of the lungs.  Possible causes include\ninhalation exposures\norgan transplantation\ncertain drugs, and\ncollagen vascular disorders.\nThe following are common findings in constrictive bronchiolitis.\nAffected individuals are comfortable at rest and able to perform activities of daily living.\nX-rays can be normal.\nPFTs can be normal or near-normal.\nIn spite of normal x-rays and PFTs, the in-service symptoms and complaints often include\nshortness of breath on physical exertion\ninability to meet physical training requirements, and/or\na finding of unfitness for deployment.\nIn some cases, symptoms can be incorrectly attributed to asthma or COPD.\nConstrictive bronchiolitis does not have its own DC.  Select an appropriate analogous DC, such as\n38 CFR 4.97, DC 6600 through 6604\n, when rating constrictive bronchiolitis.  Utilize a built-up, hyphenated DC, such as, 6699-6600, to reflect the use of the analogous rating.\nPFTs are the usual standard for rating respiratory disabilities.\nConsider extra-schedular evaluations in cases where there is evidence that\nan exceptional or unusual disability picture is present, and\na Veteran’s employment is affected.\nReferences\n:  For more information on\nclaims for SC for constrictive bronchiolitis associated with exposure to environmental hazards during the Gulf War era, see\nM21-1, Part VIII, Subpart ii, 3.A\nand\nB\nthe identification of constrictive bronchiolitis in individuals exposed to environmental hazards associated with the Mishraq state sulfur mine fire, see\nM21-1, Part VIII, Subpart ii, 3.B.3.c\nextra-schedular evaluations, see\nM21-1, Part V, Subpart ii, 3.D.3\n, and\nanalogous\nratings, see\n38 CFR 4.20\n, and\nDCs, see\n38 CFR 4.27\n.\nV.iii.4.A.4.g\n.\nComplete Organic Aphonia and SMC\nAward special monthly compensation (SMC) if complete organic aphonia results in the constant inability to communicate by speech.\nReference\n:  For more information\non awarding SMC for organic aphonia\n, see\n38 CFR 3.350(a)(6)\n38 CFR 4.96\n38 CFR 4.97, DC 6519\nM21-1, Part VIII, Subpart iv, 4.A.4.i\n, and\nM21-1, Part VIII, Subpart iv, 4.B.2.g\n.\nV.iii.4.A.4.h\n.\nSpontaneous Pneumothorax\nProvide an evaluation of 100 percent following episodes of total spontaneous pneumothorax as of the date of hospital admission, continuing for three months from the first day of the month after hospital discharge.\nEvaluate pneumothorax under\n38 CFR 4.97, DC 6843\n.\nV.iii.4.A.4.i\n.\nGSWs of MGs I to IV and XXI\nWhen evaluating gunshot wounds (GSWs) of muscle groups (MGs) I through IV and MG XXI, an evaluation under the general rating formula for restrictive lung disease, which covers\n38 CFR 4.97, DCs 6840 through 6845\n,\nmust\nbe considered.\nA minimum evaluation of 20 percent must be assigned if there is\na bullet or missile retained in the lung\npain or discomfort on exertion\nscattered rales\nlimitation of excursion of diaphragm, or\nlimitation of excursion of lower chest expansion.\nNotes\n:\nSeparate ratings may be awarded for MGs I through IV and ratings for respiratory impairment.\nA GSW of MG XXI will\nnot\nbe separately evaluated from the respiratory disability under restrictive lung disease criteria.  Assign a single evaluation for injury to MG XXI and any respiratory impairment.\n<--\nPrevious Section\nNext Section\n-->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014467\" articlename=\"M21-1, Part V, Subpart iii, Chapter 3 - Infectious Diseases, Immune Disorders, and Nutritional Deficiencies\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014467/M21-1-Part-V-Subpart-iii-Chapter-3-Infectious-Diseases-Immune-Disorders-and-Nutritional-Deficiencies\">&lt;-- <strong>Previous Section</strong></a>  <a articleid=\"554400000180881\" articlename=\"M21-1, Part V, Subpart iii, Chapter 4, Section B - Tuberculosis\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180881/M21-1-Part-V-Subpart-iii-Chapter-4-Section-B-Tuberculosis\"><strong>Next Section </strong>--&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Section</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This section contains the following topics:</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 470px; border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 423px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1</span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Basic Rating Principles for Respiratory Conditions</span></span></a></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 1px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></td><td style=\"width: 423px; text-align: center; padding: 1px;\"><div style=\"text-align: left\"><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Sleep Apnea and Related Disabilities</span></span></a></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 1px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">3</span></span></td><td style=\"width: 423px; text-align: center; padding: 1px;\"><div style=\"text-align: left\"><a href=\"#3\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Respiratory Tract Infections</span></span></a></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 1px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">4</span></span></td><td style=\"width: 423px; text-align: center; padding: 1px;\"><div style=\"text-align: left\"><a href=\"#4\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Other Respiratory Disorders</span></span></a></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><p class=\"ng-scope\"> <br/> </p><h2 class=\"ng-scope\"> <span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  Basic Rating Principles for Respiratory Conditions</span></span></h2><p class=\"ng-scope\"> <br/> </p><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains basic rating principles for respiratory conditions, including</span></span></div><ul><li><div><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">prohibition of separate evaluations for certain coexisting respiratory disabilities</span></span></a></div></li><li><div><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating coexisting respiratory disabilities</span></span></a></div></li><li><div><a href=\"#1c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">example 1 - evaluating coexisting respiratory disabilities</span></span></a></div></li><li><div><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">example 2 - evaluating coexisting respiratory disabilities</span></span></a></div></li><li><div><a href=\"#1e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">requirement for pulmonary function tests (PFTs)</span></span></a></div></li><li><div><a href=\"#1f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">assigning disability evaluations based on the results of PFTs</span></span></a></div></li><li><div><a href=\"#1g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">post-bronchodilator studies, requirements, and evaluations</span></span></a><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1h\" target=\"_self\">diffusion capacity of the lung for carbon monoxide (DLCO) testing</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">April 18, 2018</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.1.a<a id=\"1a\" name=\"1a\">.</a>  Prohibition of Evaluations for Certain Coexisting Respiratory Disabilities</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(a)</a> prohibits the assignment of separate evaluations for co-existing respiratory conditions rated under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, diagnostic codes (DCs) 6600 through 6817 and 6822 through 6847</a>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DCs 6819 and 6820</a> (malignant and benign neoplasms) are rated on residuals, including any residual disability of the respiratory system.  Therefore, where there is lung or pleural involvement, separate evaluations under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DCs 6819 and 6820</a> are prohibited.  If an evaluation has already been assigned under either <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DCs 6819 or 6820</a>, separate evaluations are also prohibited under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DCs 6600 through 6817 and 6822 through 6847</a>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on pyramiding, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.14</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.b</a>, and</span></span></div></li><li><div><a articleid=\"554400000066775\" articlename=\"Esteban v. Brown, February 25, 1994, 6 Vet.App. 259 (1994)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000066775/Esteban-v-Brown-February-25-1994-6-VetApp-259-1994\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>Esteban v. Brown</em></span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">, 6 Vet.App. 259 (1994).</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.1.b<a id=\"1b\" name=\"1b\">.</a>  Evaluating Coexisting Respiratory Disabilities</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(a)</a>, when there are coexisting respiratory disabilities for which multiple evaluations cannot be assigned</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">a single rating will be assigned under the DC which reflects the predominant disability, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">that evaluation will be elevated to the next higher evaluation, when the severity of the overall disability warrants it. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Exception</em></strong>:  In cases protected by the provisions of <em>Pub</em><em>lic Law 90-493</em>, the graduated ratings of 50 and 30 percent for inactive tuberculosis will not be elevated.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The Veterans Benefits Management System – Rating Evaluation Builder is programmed to appropriately apply the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=ea228608dbe085d5fbd6e4c2d73698f1&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_196\" target=\"_blank\">38 CFR 4.96(a)</a> <strong><em>but</em></strong> it is critical that</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the user input the symptoms that support the elevation, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the symptoms coincide with the criteria listed in the rating schedule. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Refer to the table below for instructions on proper application of the <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(a)</a> provision on assigning an evaluation in cases of multiple qualifying coexisting respiratory disabilities.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides instructions on proper application of the 38 CFR 4.96(a) provision on assigning an evaluation in cases of multiple qualifying coexisting respiratory disabilities.\" width=\"510\"><thead><tr><th scope=\"col\" style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Step</strong></span></span></div></th><th scope=\"col\" style=\"width: 438px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Action</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Determine which of the coexisting respiratory conditions is the predominant disability. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">To determine the predominant disability, determine the evaluation each condition would warrant on its own.  The condition that has the highest disability evaluation is the predominant disability.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the same evaluation would be assigned to each, go through the analysis in the steps, alternatively treating each condition as the predominant one to see if one alternative provides a more advantageous outcome to the Veteran.  </span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Determine if there are symptoms of the non-predominant disability that do not overlap with those of the predominant disability.</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If <em>yes</em>, go to Step 3.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If <em>no</em>, go to Step 4.</span></span></span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">3</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Reevaluate the predominant disability but this time also consider the non-overlapping symptoms of the non-predominant disability. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  The non-overlapping symptoms must support a higher evaluation when applied to the DC criteria being utilized for the predominant disability. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Determine if the resultant evaluation is higher than the evaluation for the symptoms of the predominant disability alone (as derived in Step 1).</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If <em>yes</em>, go to Step 5.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If <em>no</em>, go to Step 4.</span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">4</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Rate the coexistent disabilities together under the rating criteria for the predominant disability <em>without elevation</em> to the next higher evaluation.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">No further action necessary. </span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">5</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Rate the coexistent disabilities together under the rating criteria for the predominant disability and elevate to the next higher evaluation.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">No further action necessary. </span></span></div></li></ul></td></tr></tbody></table><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The “next higher level of evaluation” is the lowest evaluation specified in the DC for the predominant disability <em>that provides greater compensation than the evaluation derived in </em><em>Step 1</em> (the evaluation that would be supported by only the symptoms of the predominant disability without the symptoms of the lesser disability).  <em><strong>Do not simply add 10 percent.</strong></em></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Although elevation remains a legal option under the existing regulatory language, because evaluations in the specified DCs overwhelmingly use mostly-overlapping and mostly-objective criteria, in many cases the result of the analysis specified in the table will be a conclusion that elevation is not appropriate.  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on application of <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=17cf8fa6451a40f263917eb92169f72b&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(a)</a>, see <a articleid=\"554400000069924\" articlename=\"Urban v. Shulkin, Sep 18, 2017, 29 Vet.App. 82\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000069924/Urban-v-Shulkin-Sep-18-2017-29-VetApp-82\"><em>Urban v. Shulkin</em></a>, 29 Vet.App. 82 (2017).</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.1.c<a id=\"1c\" name=\"1c\">.</a>  Example 1 - Evaluating Coexisting Respiratory Disabilities</span></span></strong></h3><h3></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Situation</em></strong>:  Sleep apnea (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6847</a>) warrants an evaluation of 50 percent based on the need for a continuous positive airway pressure (CPAP) machine.  Chronic obstructive pulmonary disease (COPD) (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6604</a>) is coexistent and warrants a 30-percent evaluation based on pulmonary function tests (PFTs). </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Result</em></strong>:  The predominant condition is the sleep apnea as it justifies a higher evaluation.  There are no non-overlapping symptoms of COPD to establish any of the criteria for which the next higher (100 percent) evaluation could be assigned for sleep apnea:  chronic respiratory failure with carbon dioxide retention or cor pulmonale, or need for tracheostomy.  Therefore, elevation is not appropriate.  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.1.d<a id=\"1d\" name=\"1d\">.</a>  Example 2 - Evaluating Coexisting Respiratory Disabilities</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Situation</em></strong>:  Asbestosis (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6833</a>) warrants an evaluation of 30 percent based on diffusion capacity of the lung for carbon monoxide (DLCO).  Asthma (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6602</a>) is coexistent and warrants a 30-percent evaluation based on inhalational anti-inflammatory medication.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Result</em></strong>:  Neither is predominant as each would justify a 30-percent evaluation.   The use of medications is not considered in next higher criteria for <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6833</a> (Forced Vital Capacity (FVC) of 50 to 64 percent of predicted; DLCO of 40-55 percent of predicted; or, maximum exercise capacity of less than 15 ml/kg/min of oxygen consumption with cardiorespiratory limitation) and does not provide any basis for elevation. Conversely, the DLCO result for asbestosis is not considered in the next higher criteria for <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6602</a> (Forced Expiratory Volume in one second (FEV-1) of 40 to 55 percent predicted; FEV-1/FVC of 40 to 55 percent; at least monthly visits to a physician for required care of exacerbations; or, intermittent (at least three per year) courses of systemic (oral or parenteral) corticosteroids).  Therefore, elevation is not appropriate.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.1.e<a id=\"1e\" name=\"1e\">.</a> Requirement for PFTs</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">PFT results are required for <a href=\"https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=2e4b9c12bdf152d9040f44c2ab4f7d02&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_197\" target=\"_blank\">38 CFR 4.97, DC 6600, 6603, 6604, 6825-6833, and 6840-6845</a> as specified at <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=b94cb76797b82609402ed7341063c795&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(d)</a> except when</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the results of a maximum exercise capacity test are of record and are 20 milliliters/per kilogram of body weight per minute (ml/kg/min) or less</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pulmonary hypertension has been diagnosed</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">cor pulmonale has been diagnosed</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">right ventricular hypertrophy has been diagnosed</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">there have been one or more episodes of acute respiratory failure, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">outpatient oxygen therapy is required.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If a maximum exercise capacity test is not of record, evaluate based on alternative criteria.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A diagnosis of pulmonary hypertension requires objective documentation by an echocardiogram or cardiac catheterization.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When the rating criteria for a disability not regulated by <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(d)</a> include PFTs among the potential methods for assigning a disability evaluation, such as <a href=\"https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=2e4b9c12bdf152d9040f44c2ab4f7d02&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_197\" target=\"_blank\">38 CFR 4.97, DC 6602</a> for asthma, PFTs are not required to evaluate the disability.  However, if PFTs were previously utilized to assign a disability evaluation and consideration is being given to a reduced evaluation, apply <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=327da99ab8b0bc42db49bab2445cc240&amp;mc=true&amp;node=se38.1.3_1344&amp;rgn=div8\" target=\"_blank\">38 CFR 3.344(a)</a>.  When the prior evaluation was assigned based on PFTs, the current examination must also include PFTs if a reduced evaluation due to improvement is being considered</span></span>.</div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on when PFTs are required, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(d)</a>. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.1.f<a id=\"1f\" name=\"1f\">.</a> Assigning Disability Evaluations Based on the Results of PFTs</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The table below contains instructions for assigning disability evaluations based on the results of PFTs. </span></span> <span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This table applies to <a href=\"https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=2e4b9c12bdf152d9040f44c2ab4f7d02&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_197\" target=\"_blank\">38 CFR 4.97, DC 6600, 6603, 6604, 6825-6833, and 6840-6845</a> as specified at <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=b94cb76797b82609402ed7341063c795&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96(d)</a>.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 501px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is an if-and-then table.  Column 1 provides the first criteria, column 2 provides the second criteria, and column 3 provides instructions for assigning disability evaluations based on the results of PFTs.\" width=\"501\"><thead><tr><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>If …</strong></span></span></div></th><th scope=\"col\" style=\"width: 162px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>And …</strong></span></span></div></th><th scope=\"col\" style=\"width: 174px; padding: 1px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Then ...</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">PFTs are not consistent with clinical findings</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the examiner <em>does</em> <em>not</em> state why PFTs are not a valid indication of respiratory disability</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluate based on PFTs.</span></span></div></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">PFTs are not consistent with clinical findings</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the examiner states why PFTs are not a valid indication of respiratory disability</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluate based on alternative criteria.</span></span></div></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">there is a disparity between PFT results  (FEV-1, FVC, FEV-1/FVC, DLCO)</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the evaluation would differ depending on the test result used</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">use the test result that the examiner states most accurately reflects the level of disability.</span></span></div></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">FEV-1 is greater than 100 percent</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">FVC is greater than 100 percent</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">do not assign a compensable evaluation based on a decreased FEV-1/FVC ratio.</span></span></div></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">DLCO is not of record</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the examiner states why DLCO would not be useful or valid</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluate based on alternative criteria.</span></span></div></td></tr><tr><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">DLCO is not of record</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the examiner <em>does not</em> state why DLCO would not be useful or valid</span></span></div></td><td style=\"width: 174px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">return the examination as insufficient and request clarification.</span></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.1.g<a id=\"1g\" name=\"1g\">.</a> Post-Bronchodilator Studies, Requirements, and Evaluations</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Post-bronchodilator studies are required when PFTs are done for disability evaluation purposes </span><span style=\"font-family: arial, helvetica, sans-serif\">for disabilities rated under <a href=\"https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&amp;SID=2e4b9c12bdf152d9040f44c2ab4f7d02&amp;mc=true&amp;r=SECTION&amp;n=se38.1.4_197\" target=\"_blank\">38 CFR 4.97, DC 6600, 6603, 6604, 6825-6833, and 6840-6845</a></span><span style=\"font-family: arial , helvetica , sans-serif\"> <em>except</em> when</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the results of pre-bronchodilator PFTs are normal</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the examiner determines that post-bronchodilator studies should not be done and states why, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">using the DLCO score values (Clinicians have stated that bronchodilator use has no effect on DLCO values.)</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When evaluating based on PFTs, use post-bronchodilator results unless the post-bronchodilator results were poorer than the pre-bronchodilator results.  In those cases, use the pre-bronchodilator values for rating purposes.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.1.h<a id=\"1h\" name=\"1h\">.</a> DLCO Testing</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When utilizing DLCO to evaluate a respiratory disability, only test results recognized as DLCO or DLCO by the single breath method (DLCO (SB)) will be utilized for rating purposes. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">DLCO divided by alveolar volume (DLCO/VA) is a variant of DLCO (SB) in which the DLCO is divided by the alveolar volume of the lungs. There is no provision for considering DLCO/VA under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=f0610b792b88e7414191c0286df17049&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96</a> or <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=f0610b792b88e7414191c0286df17049&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97</a>. Consequently, DLCO/VA cannot be utilized for rating purposes.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\"> <br/> </p><h2 class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 16px\"><strong>2<a id=\"2\" name=\"2\">.</a>  </strong>Sleep Apnea and Related Disabilities</span></span></h2><div class=\"ng-scope\"> <br/> </div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Introduction</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains general information about sleep apnea and related disabilities, including<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sleep apnea and sleep studies</span></span></a></div></li><li><div><a href=\"#2b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating sleep apnea</span></span></a></div></li><li><div><a href=\"#2c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">qualifying devices for sleep apnea treatment</span></span></a></div></li><li><div><a href=\"#2d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">required use of a breathing assistance device</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2e\" target=\"_self\">processing claims for increase in sleep apnea</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2f\" target=\"_self\">considering upper airway resistance syndrome (UARS)</a>. </span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">February 19, 2019</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.2.a<a id=\"2a\" name=\"2a\">.</a>  Sleep Apnea and Sleep Studies</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Receipt of medical evidence disclosing a diagnosis of sleep apnea without confirmation by a sleep study is sufficient to trigger the duty to assist for scheduling an examination if the other provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=75e91c496dce5ed5644ffe9c98fc27aa&amp;mc=true&amp;node=se38.1.3_1159&amp;rgn=div8\" target=\"_blank\">38 CFR 3.159(c)(4)</a> have been satisfied.  However, such evidence is <em>not</em> sufficient to award service connection (SC) for sleep apnea. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When clinical examination leads to the conclusion that symptoms of sleep apnea are present, the subsequent diagnosis of sleep apnea must be confirmed by sleep study for compensation purposes. </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Do not establish SC for sleep apnea that has not been confirmed by a sleep study. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">However, if clinical indicators of sleep apnea are not found on examination, a sleep study is not required to rule out the sleep apnea diagnosis. </span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Important</em></strong>:  Accept a home sleep study only if</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">it has been clinically determined that the Veteran can be appropriately evaluated by a home sleep study, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">a competent medical provider has evaluated the results. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on types of medical providers qualified to provide medical evidence, see </span></span><a articleid=\"554400000180514\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section A - General Criteria for Sufficiency of Examination Reports\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180514/M21-1-Part-IV-Subpart-i-Chapter-3-Section-A-General-Criteria-for-Sufficiency-of-Examination-Reports\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">M21-1, Part IV, Subpart i, 3.A.1</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>V.iii.4.A.2.b<a id=\"2b\" name=\"2b\">.</a> Evaluating Sleep Apnea</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial, helvetica, sans-serif\">Evaluate sleep apnea using the criteria in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=92ed4bdd80ecbd15b575b9b8ea7c0e7f&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6847</a> (sleep apnea syndromes (obstructive, central, mixed). </span></span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial, helvetica, sans-serif\">When determining whether the 50-percent criteria are met, the key consideration is whether use of a qualifying breathing assistance device is required by the severity of the sleep apnea.  </span></span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial, helvetica, sans-serif\">There are two related considerations, which are</span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial, helvetica, sans-serif\">whether a device qualifies, as discussed in <a href=\"#2c\" target=\"_self\">M21-1, Part V, Subpart iii, 4.A.2.c</a>, and</span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: arial, helvetica, sans-serif\">if use of a qualifying device is necessary, as discussed in <a href=\"#2d\" target=\"_self\">M21-1, Part V, Subpart iii, 4.A.2.d</a>.</span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.2.c<a id=\"2c\" name=\"2c\">.</a>  Qualifying Devices for Sleep Apnea Treatment </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=92ed4bdd80ecbd15b575b9b8ea7c0e7f&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6847</a> lists a CPAP machine as an example of a breathing assistance device for treatment of sleep apnea which is required for assignment of the 50 percent evaluation. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Other qualifying breathing assistance devices include<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">other positive airway pressure machines (automatic positive airway pressure device (APAP); bilevel positive airway pressure device (BiPAP)) </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">nasopharyngeal appliances (nasal dilators; nasopharyngeal stents)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">oral appliances (mandibular advancement devices (MAD); tongue-retaining mouthpieces), and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">implanted genioglossal nerve stimulation devices.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Positive airway pressure machines may also be called non-invasive positive pressure ventilation (NIPPV) or non-invasive ventilation (NIV).</span></span></span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.2.d<a id=\"2d\" name=\"2d\">.</a>  Required Use of a Breathing Assistance Device</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Assignment of the 50-percent evaluation for sleep apnea under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=92ed4bdd80ecbd15b575b9b8ea7c0e7f&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6847</a> entails the required use of a breathing assistance device.  Consider the factors below in determining whether the criteria for required use of a breathing assistance device are satisfied. <span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Use of a device absent a medical determination that the device is necessary does not qualify.  The regulation requires that the device be necessary, and this is a medical question. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If the competent medical evidence of record shows that use of a qualifying breathing assistance device is medically required, the fact that the claimant is not actually using it as prescribed is not relevant. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.2.e<a id=\"2e\" name=\"2e\">.</a> Processing Claims for Increase in Sleep Apnea</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Follow the steps in the table below to process a claim for increase in sleep apnea.</span></span></div><div></div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 496px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a step-action table.  Column 1 is the step number and column 2 provides the actions to take to process a claim for increase in sleep apnea.\" width=\"496\"><thead><tr><th scope=\"col\" style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Step</strong></span></span></div></th><th scope=\"col\" style=\"width: 438px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Action</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1</span></span></div></td><td style=\"width: 438px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Is there a sleep study confirming the diagnosis of sleep apnea?</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>yes</em>, go to Step 6.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If<em> no</em>, go to Step 2.</span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">2</span></span></div></td><td style=\"width: 438px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Has SC for sleep apnea been in effect for 10 years or more?</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>yes</em>, go to Step 6.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>no</em>, go to Step 3.</span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">3</span></span></div></td><td style=\"width: 438px; padding: 1px;\"><ul><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Request an examination with sleep study to confirm the diagnosis. </span></span></div></li><li><div><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">Go to Step 4.</span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">4</span></span></div></td><td style=\"width: 438px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Does the sleep study confirm the diagnosis of sleep apnea?</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>yes</em>, go to Step 6.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If <em>no</em>, go to Step 5.</span></span></div></li></ul></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">5</span></span></div></td><td style=\"width: 438px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Prepare a proposal to sever SC for sleep apnea in accordance with <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=75e91c496dce5ed5644ffe9c98fc27aa&amp;mc=true&amp;node=se38.1.3_1105&amp;rgn=div8\" target=\"_blank\">38 CFR 3.105(d)</a>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on preparing proposed rating decisions, see <a articleid=\"554400000177968\" articlename=\"M21-1, Part X, Subpart ii, Chapter 3, Section D - Completing Proposed Rating Decisions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177968/M21-1-Part-X-Subpart-ii-Chapter-3-Section-D-Completing-Proposed-Rating-Decisions\">M21-1, Part X, Subpart ii, 3.D.1</a>.</span></span></div></td></tr><tr><td style=\"width: 72px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">6</span></span></div></td><td style=\"width: 438px; vertical-align: top; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Perform any additional development as necessary, continue SC for sleep apnea, and assign an evaluation based on the evidence of record.</span></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\">V.iii.4.A.2.f<a id=\"2f\" name=\"2f\">.</a>  Considering UARS</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Upper airway resistance syndrome (UARS) represents a progression toward the potential development of sleep apnea, caused by snoring.  However, UARS, in and of itself, does not meet the criteria of sleep-disordered breathing that defines sleep apnea and is not considered a ratable disability for compensation purposes.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In order to dispose of a claim for SC where only an assessment of UARS is shown, the rating activity must</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">deny SC in the absence of a diagnosed chronic disability</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">code the issue as analogous to sleep apnea under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=92ed4bdd80ecbd15b575b9b8ea7c0e7f&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6847</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">inform the Veteran that a supplemental claim may be submited if a clinical diagnosis of sleep apnea is subsequently confirmed.</span></span></span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example</em></strong>: </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><img alt=\"Image of DC on rating codesheet.\" src=\"/img/cpkm/III.iv.4.D.1.q.png\" style=\"border-top: 1px solid; height: 68px; border-right: 1px solid; width: 510px; border-bottom: 1px solid; border-left: 1px solid\"/> </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">subthreshold diagnoses, see <a articleid=\"554400000180488\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section C - Reviewing Diagnoses\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180488/M21-1-Part-V-Subpart-ii-Chapter-3-Section-C-Reviewing-Diagnoses\">M21-1, Part V, Subpart ii, 3.C.1.b</a></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sleep disorders examination review, see <a articleid=\"554400000180516\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section B - Examination Sufficiency for Specific Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180516/M21-1-Part-IV-Subpart-i-Chapter-3-Section-B-Examination-Sufficiency-for-Specific-Disabilities\">M21-1, Part IV, Subpart i, 3.B.1.l</a>, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">using analogous DCs, see </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000180525\" articlename=\"M21-1, Part V, Subpart iv, Chapter 1, Section C - Coded Conclusion\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180525/M21-1-Part-V-Subpart-iv-Chapter-1-Section-C-Coded-Conclusion\">M21-1, Part V, Subpart iv, 1.C.2.a and b</a>, and</span></span></span></span></div></li><li><div><a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">M21-1, Part V, Subpart ii, 3.D.1.b</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div class=\"ng-scope\"></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>3<a id=\"3\" name=\"3\">.</a>  </strong></span><span style=\"font-family: arial, helvetica, sans-serif\">Respiratory Tract Infections</span></span><br/> </h2><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Introduction</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains general information about respiratory tract infections, including<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">types of chronic upper respiratory tract infections</span></span></a></div></li><li><div><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">identifying the cause of coexisting chronic upper respiratory tract infections</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3c\" target=\"_self\">continuous upper respiratory tract infections that first manifest after discharge</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3d\" target=\"_self\">relationship between upper and lower respiratory tract infections</a>. </span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">January 31, 2018 </span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.3.a<a id=\"3a\" name=\"3a\">.</a>  Types of Chronic Upper Respiratory Tract Infections</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Chronic upper respiratory tract infections include</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">chronic rhinitis</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">chronic sinusitis</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">chronic tonsillitis, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">chronic laryngitis.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.3.b<a id=\"3b\" name=\"3b\">.</a>  Identifying the Cause of Coexisting Chronic Upper Respiratory Tract Infections</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The cause of two or more coexisting chronic upper respiratory tract infections is commonly the same infectious process.  However, if two or more chronic infections persist over a period of years, give the probability of causation by separate types of organisms due weight.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.3.c<a id=\"3c\" name=\"3c\">.</a>  Continuous Upper Respiratory Tract Infections That First Manifest After Discharge</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If all respiratory conditions do not originate in service, there must be evidence of a fairly continuous infection in one or more parts of the upper respiratory tract to warrant SC for other conditions first manifest after discharge.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Carefully consider the character of the infection and possible intervening causes.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.3.d<a id=\"3d\" name=\"3d\">.</a>  Relationship Between Upper and Lower Respiratory Tract Infections</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">There may be a close relationship between disease of the upper respiratory tract and a subsequently-developing chronic process in the lower respiratory tract, especially in the bronchi.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div class=\"ng-scope\"></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>4<a id=\"4\" name=\"4\">.</a>  </strong></span><span style=\"font-family: arial, helvetica, sans-serif\">Other Respiratory Disabilities</span></span></h2><div class=\"ng-scope\"> <br/> </div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Introduction</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains general information about other respiratory disabilities, including<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><a href=\"#4a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">deviated nasal septum</span></span></a></div></li><li><div><a href=\"#4b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sinusitis</span></span></a></div></li><li><div><a href=\"#4c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering allergic rhinitis within scope of claimed sinusitis</span></span></a></div></li><li><div><a href=\"#4d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">rhinosinusitis</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">allergic rhinitis</span></span></a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">constrictive bronchiolitis</span></span></a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">complete organic aphonia and special monthly compensation (SMC)</span></span></a></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4h\" target=\"_self\">spontaneous pneumothorax</a>, and</span></span></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4i\" target=\"_self\">gunshot wounds (GSWs) of muscle groups (MGs) I to IV and XXI</a>. </span></span></span></span></span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">April 22, 2022</span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.4.a<a id=\"4a\" name=\"4a\">.</a>  Deviated Nasal Septum</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">SC cannot be granted for a deviation of the nasal septum unless trauma is shown.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on traumatic nasal septum deviation see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=92ed4bdd80ecbd15b575b9b8ea7c0e7f&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6502</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.4.b<a id=\"4b\" name=\"4b\">.</a>  Sinusitis</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Evaluate sinusitis under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DCs 6510 through 6514</a>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When applying the higher of two possible evaluations under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_17&amp;rgn=div8\" target=\"_blank\">38 CFR 4.7</a>, a history of radical surgery or repeated surgeries is <em>not</em> required if the criteria under the rating formula are otherwise met.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Example</em></strong>:  The application of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_17&amp;rgn=div8\" target=\"_blank\">38 CFR 4.7</a> results in an evaluation of 50 percent when the evidence shows</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">chronic osteomyelitis, <em>or</em></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">near constant sinusitis, characterized by</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">headaches</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pain and tenderness of affected sinus, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">purulent discharge, <em>and</em></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">no evidence of radical surgery or repeated surgery.<span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on the schedule of rating respiratory conditions, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.4.c<a id=\"4c\" name=\"4c\">.</a>  Considering Allergic Rhinitis Within Scope of Claimed Sinusitis</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When a claim for SC for sinusitis is received but compensation examination reveals a diagnosis of allergic rhinitis and not sinusitis and associates the rhinitis with service, consider allergic rhinitis within scope of the claim for SC for sinusitis.  In this situation<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">do not return the examination for clarification of a diagnosis if the examination is otherwise sufficient</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">grant SC for allergic rhinitis if otherwise supported by the evidence of record, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">deny SC for sinusitis if sinusitis is not shown. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reminder</em></strong>:  If both sinusitis and rhinitis are shown and the requirements for SC are met for both conditions, grant SC for each condition separately and  combine as usual under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=e815c842d6d745ce452c78742f849eba&amp;mc=true&amp;node=se38.1.4_125&amp;rgn=div8\" target=\"_blank\">38 CFR 4.25</a>. </span></span></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on considering issues within scope of a claim, see</span></span></div><ul><li><div><a articleid=\"554400000180486\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section A - Determining the Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180486/M21-1-Part-V-Subpart-ii-Chapter-3-Section-A-Determining-the-Issues\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">M21-1, Part V, Subpart ii, 3.A.2</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=7833c2e3bc614bde74c955d43413090e&amp;mc=true&amp;node=se38.1.3_1155&amp;rgn=div8\" target=\"_blank\">38 CFR 3.155(d)(2)</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.4.A.4.d<a id=\"4d\" name=\"4d\">.</a>  Rhinosinusitis</span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Rhinosinusitis should be rated as a type of sinusitis, using the general rating formula and choosing the most appropriate DC from <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR14fb86bcc86c2cb/section-4.97\" target=\"_blank\">38 CFR 4.97, DC 6510 through 6514</a>.  Select the DC for the type of sinusitis that most closely corresponds with the location of the rhinosinusitis.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Note</i></b>:</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">DC 6599 analogous code indicator should precede the analogous sinusitis DC because rhinosinusitis is not listed in the rating schedule.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Rhinosinutis is a chronic disease associated with exposure to particulate matter, as provided in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.320\" target=\"_blank\">38 CFR 3.320(a)(2)</a>.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Reference</i></b>:  For more information on claims for SC for chronic diseases associated with exposure to particulate matter, see <a articleid=\"554400000177441\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 2, Section A - General Information on Claims Based on Exposure to Burn Pits and Other Toxins, Including Fine Particulate Matter (BPOT)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177441/M21-1-Part-VIII-Subpart-ii-Chapter-2-Section-A-General-Information-on-Claims-Based-on-Exposure-to-Burn-Pits-and-Other-Toxins-Including-Fine-Particulate-Matter-BPOT\">M21-1, Part VIII, Subpart ii, 2.A</a>-<a articleid=\"554400000177443\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 2, Section C - Rating Claims Based on Exposure to Burn Pits and Other Toxins, Including Fine Particulate Matter (BPOT)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177443/M21-1-Part-VIII-Subpart-ii-Chapter-2-Section-C-Rating-Claims-Based-on-Exposure-to-Burn-Pits-and-Other-Toxins-Including-Fine-Particulate-Matter-BPOT\">C</a>.</span></span></div></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.4.A.4.e<a id=\"4e\" name=\"4e\">.</a>  Allergic Rhinitis</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=7833c2e3bc614bde74c955d43413090e&amp;mc=true&amp;node=se38.1.3_1380&amp;rgn=div8\" target=\"_blank\">38 CFR 3.380</a> directs that diseases of allergic etiology are not to be disposed of routinely for compensation purposes as constitutional or developmental abnormalities.  When considering SC for allergic rhinitis, consider whether<span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the disability existed prior to service, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">whether the disability is chronic and persistent in relation to exposure to and removal from the allergen.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The determination as to service incurrence must be based on the whole evidentiary showing.</span></span></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example</em></strong>:  Veteran claims SC for allergic rhinitis.  The nose and sinuses were normal at enlistment with no allergies noted.  During his 20-year military career, the Veteran was treated variably for symptoms of upper respiratory infection, congestion, rhinitis, seasonal allergic rhinitis, perennial allergic rhinitis, and seasonal allergies throughout service.  Clear diagnoses of allergies and allergic rhinitis were noted during service including on the retirement physical.  At the compensation examination, the Veteran reported episodic sinusitis and ongoing allergic rhinitis with seasonal symptoms and the use of medications for treatment.  Examination revealed no obstruction or deviation.  No rhinitis or sinusitis were active on examination.  The diagnosis was seasonal allergic rhinitis. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Result</em></strong>:  The Veteran had a long and recurring history of complaints of, treatment for, and diagnosis of allergic rhinitis and upper respiratory symptoms during service.  There is no evidence of a pre-service history of allergic rhinitis.  Veteran is entitled to SC with a noncompensable evaluation for allergic rhinitis as evidence showed incurrence in service.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.4.A.4.f<a id=\"4f\" name=\"4f\">.</a>  Constrictive Bronchiolitis</span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Constrictive bronchiolitis (also known as bronchiolitis obliterans) is an inflammatory and fibrotic lesion of the terminal bronchioles of the lungs.  Possible causes include</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">inhalation exposures</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">organ transplantation</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">certain drugs, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">collagen vascular disorders.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The following are common findings in constrictive bronchiolitis.</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Affected individuals are comfortable at rest and able to perform activities of daily living.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">X-rays can be normal.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">PFTs can be normal or near-normal.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">In spite of normal x-rays and PFTs, the in-service symptoms and complaints often include</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">shortness of breath on physical exertion</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">inability to meet physical training requirements, and/or</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">a finding of unfitness for deployment.</span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">In some cases, symptoms can be incorrectly attributed to asthma or COPD.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Constrictive bronchiolitis does not have its own DC.  Select an appropriate analogous DC, such as <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR14fb86bcc86c2cb/section-4.97\" target=\"_blank\">38 CFR 4.97, DC 6600 through 6604</a>, when rating constrictive bronchiolitis.  Utilize a built-up, hyphenated DC, such as, 6699-6600, to reflect the use of the analogous rating.</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">PFTs are the usual standard for rating respiratory disabilities.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Consider extra-schedular evaluations in cases where there is evidence that</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">an exceptional or unusual disability picture is present, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">a Veteran’s employment is affected.</span></span></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>References</i></b>:  For more information on</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">claims for SC for constrictive bronchiolitis associated with exposure to environmental hazards during the Gulf War era, see <a articleid=\"554400000177445\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 3, Section A - Historical\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177445/M21-1-Part-VIII-Subpart-ii-Chapter-3-Section-A-Historical\">M21-1, Part VIII, Subpart ii, 3.A</a> and <a articleid=\"554400000177446\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 3, Section B - Historical\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177446/M21-1-Part-VIII-Subpart-ii-Chapter-3-Section-B-Historical\">B</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the identification of constrictive bronchiolitis in individuals exposed to environmental hazards associated with the Mishraq state sulfur mine fire, see <a articleid=\"554400000177446\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 3, Section B - Historical\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177446/M21-1-Part-VIII-Subpart-ii-Chapter-3-Section-B-Historical\">M21-1, Part VIII, Subpart ii, 3.B.3.c</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">extra-schedular evaluations, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.3</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">analogous</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">ratings, see <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.20\" target=\"_blank\">38 CFR 4.20</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">DCs, see <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.27\" target=\"_blank\">38 CFR 4.27</a>.</span></span></li></ul></li></ul></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.4.g<a id=\"4g\" name=\"4g\">.</a> Complete Organic Aphonia and SMC</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Award special monthly compensation (SMC) if complete organic aphonia results in the constant inability to communicate by speech.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information </span><span style=\"font-family: arial, helvetica, sans-serif\">on awarding SMC for organic aphonia</span><span style=\"font-family: arial , helvetica , sans-serif\">, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=75e91c496dce5ed5644ffe9c98fc27aa&amp;mc=true&amp;node=se38.1.3_1350&amp;rgn=div8\" target=\"_blank\">38 CFR 3.350(a)(6)</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_196&amp;rgn=div8\" target=\"_blank\">38 CFR 4.96</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6519</a> </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177480\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section A - Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177480/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-A-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.A.4.i</a>, and </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177481\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 4, Section B - History of Special Monthly Compensation (SMC)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177481/M21-1-Part-VIII-Subpart-iv-Chapter-4-Section-B-History-of-Special-Monthly-Compensation-SMC\">M21-1, Part VIII, Subpart iv, 4.B.2.g</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.4.h<a id=\"4h\" name=\"4h\">.</a>  Spontaneous Pneumothorax</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Provide an evaluation of 100 percent following episodes of total spontaneous pneumothorax as of the date of hospital admission, continuing for three months from the first day of the month after hospital discharge. </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Evaluate pneumothorax under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DC 6843</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.4.A.4.i<a id=\"4i\" name=\"4i\">.</a> GSWs of MGs I to IV and XXI</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When evaluating gunshot wounds (GSWs) of muscle groups (MGs) I through IV and MG XXI, an evaluation under the general rating formula for restrictive lung disease, which covers <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&amp;mc=true&amp;node=se38.1.4_197&amp;rgn=div8\" target=\"_blank\">38 CFR 4.97, DCs 6840 through 6845</a>, <em>must</em> be considered.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A minimum evaluation of 20 percent must be assigned if there is</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">a bullet or missile retained in the lung</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pain or discomfort on exertion</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">scattered rales</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">limitation of excursion of diaphragm, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">limitation of excursion of lower chest expansion.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>:  </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Separate ratings may be awarded for MGs I through IV and ratings for respiratory impairment.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">A GSW of MG XXI will <em>not</em> be separately evaluated from the respiratory disability under restrictive lung disease criteria.  Assign a single evaluation for injury to MG XXI and any respiratory impairment.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 1.2in\"></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014467\" articlename=\"M21-1, Part V, Subpart iii, Chapter 3 - Infectious Diseases, Immune Disorders, and Nutritional Deficiencies\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014467/M21-1-Part-V-Subpart-iii-Chapter-3-Infectious-Diseases-Immune-Disorders-and-Nutritional-Deficiencies\">&lt;-- <strong>Previous Section</strong></a>  <a articleid=\"554400000180881\" articlename=\"M21-1, Part V, Subpart iii, Chapter 4, Section B - Tuberculosis\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180881/M21-1-Part-V-Subpart-iii-Chapter-4-Section-B-Tuberculosis\"><strong>Next Section </strong>--&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=ea228608dbe085d5fbd6e4c2d73698f1&mc=true&r=SECTION&n=se38.1.4_196",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=75e91c496dce5ed5644ffe9c98fc27aa&mc=true&node=se38.1.3_1105&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=75e91c496dce5ed5644ffe9c98fc27aa&mc=true&node=se38.1.3_1159&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=75e91c496dce5ed5644ffe9c98fc27aa&mc=true&node=se38.1.3_1350&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=92ed4bdd80ecbd15b575b9b8ea7c0e7f&mc=true&node=se38.1.4_197&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&mc=true&node=se38.1.4_114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&mc=true&node=se38.1.4_17&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&mc=true&node=se38.1.4_196&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=fba5f58206272739e8530dca72f7e5de&mc=true&node=se38.1.4_197&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=2e4b9c12bdf152d9040f44c2ab4f7d02&mc=true&r=SECTION&n=se38.1.4_197",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=17cf8fa6451a40f263917eb92169f72b&mc=true&node=se38.1.4_196&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=327da99ab8b0bc42db49bab2445cc240&mc=true&node=se38.1.3_1344&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=7833c2e3bc614bde74c955d43413090e&mc=true&node=se38.1.3_1155&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=7833c2e3bc614bde74c955d43413090e&mc=true&node=se38.1.3_1380&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=92ed4bdd80ecbd15b575b9b8ea7c0e7f&mc=true&node=se38.1.4_197&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=b94cb76797b82609402ed7341063c795&mc=true&node=se38.1.4_196&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=e815c842d6d745ce452c78742f849eba&mc=true&node=se38.1.4_125&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=f0610b792b88e7414191c0286df17049&mc=true&node=se38.1.4_196&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=f0610b792b88e7414191c0286df17049&mc=true&node=se38.1.4_197&rgn=div8",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.320",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.20",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.27",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFR14fb86bcc86c2cb/section-4.97"
  ],
  "scraped_at": "2025-06-16T22:44:30.263101",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180881/M21-1-Part-V-Subpart-iii-Chapter-4-Section-B-Tuberculosis"
}